Bruised and battered by its failings with the controversial Alzheimer’s drug Aduhelm, Biogen is looking to right the ship with a new helmsman. The company is on the hunt for a new chief executive officer.
https://www.pharmalive.com/wp-content/uploads/2022/05/BiospaceMichaelYounatsos.jpg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-05-03 12:10:292022-05-03 12:34:36Vounatsos out as Biogen appears to concede defeat over Aduhelm